Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $154.4 million.

  • BridgeBio Pharma's Total Current Liabilities rose 55.59% to $216.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.6 million, marking a year-over-year increase of 55.59%. This contributed to the annual value of $154.4 million for FY2024, which is 7.34% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Total Current Liabilities of $154.4 million as of FY2024, which was up 7.34% from $143.8 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Total Current Liabilities peaked at $154.4 million during FY2024, and registered a low of $95.6 million during FY2020.
  • For the 3-year period, BridgeBio Pharma's Total Current Liabilities averaged around $139.9 million, with its median value being $143.8 million (2023).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first spiked by 58.40% in 2020, then fell by 10.10% in 2022.
  • BridgeBio Pharma's Total Current Liabilities (Yearly) stood at $95.6 million in 2020, then skyrocketed by 41.21% to $135.1 million in 2021, then declined by 10.10% to $121.4 million in 2022, then climbed by 18.46% to $143.8 million in 2023, then rose by 7.34% to $154.4 million in 2024.